- Positive results from the TELLOMAK Phase 2 Trial with
lacutamab in heavily pretreated patients with relapsed and
refractory Sézary syndrome selected for oral presentation
- Preliminary monotherapy lacutamab Phase 1b clinical data and
pre-clinical combinability data in patients with peripheral T-cell
lymphoma
- Presentation on SAR443579 / IPH6101, a potential
first-in-class NKp46/CD16-based NK cell engager targeting CD123;
SAR443579 / IPH6101 is ANKET® platform lead asset and under
development by partner Sanofi, which demonstrated clinical
remissions
Regulatory News:
Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA)
(“Innate” or the “Company”) today announced that
several abstracts, including one oral presentation, have been
selected for the 65th ASH (American Society of Hematology) Annual
Meeting and Exposition, taking place December 9-12, 2023 in San
Diego, California.
Lacutamab in patients with T-cell Lymphomas
- Abstract details from the TELLOMAK Phase 2 Trial in Patients
with Advanced Sézary syndrome include:
The oral presentation will highlight the results from Cohort 1,
designed to evaluate safety and efficacy of single agent lacutamab
in 56 patients with relapsed/refractory Sézary syndrome after at
least two prior systemic therapies including mogamulizumab. At the
data cut-off of May 1, 2023, with a global confirmed Objective
Response Rate (ORR) of 37.5% (n=21; 95% CI 26.0-50.6) including 2
Complete Responses (CRs), confirmed ORR in skin of 46.4% (n=26; 95%
CI 34.0-59.3) including 5 CRs and confirmed ORR in blood of 48.2%
(n=27; 95% CI 35.7-61.0) including 15 CRs, data confirm that
lacutamab monotherapy shows promising clinical activity in a
heavily pre-treated relapsed/refractory population previously
treated with a median of 6 prior lines (range 2-15), including
mogamulizumab, and an overall favorable safety profile. Clinical
Benefit Rate (CBR, defined as CR+PR+SD) was 87.5 % (n=49; 95% CI
76.4-93.8). Median PFS was 8.0 months (95% CI 4.7, 21.2). Continued
evaluation of this promising new targeted treatment option for
patients with Sezary Syndrome is warranted.
- Preliminary Monotherapy Clinical Data and Pre-Clinical
Combinability Data in Patients with Peripheral T-Cell Lymphoma
(PTCL):
The poster will display preclinical combination data supporting
anti-tumor activity and rationale for the exploration of lacutamab
in combination with approved and novel therapies in patients with
PTCL. Preliminary monotherapy data from an ongoing Phase 1b study
in PTCL is also presented.
SAR443579/IPH6101 in patients with relapsed or refractory
acute myeloid leukemia (R/R AML), B-cell acute lymphoblastic
leukemia (B-ALL) or high-risk myelodysplasia (HR-MDS) (from a Joint
Research Collaboration with Sanofi)
A presentation from the Sanofi oncology pipeline at ASH includes
updated efficacy and safety results from an open-label,
first-in-human, dose-escalation study of an investigational CD123
targeting Natural Killer Cell Engager (NKCE). Results investigating
SAR443579 as a monotherapy for the treatment of blood cancers with
high unmet needs, including relapsed or refractory acute myeloid
leukemia, B-cell acute lymphoblastic leukemia and high-risk
myelodysplasia show data across all dose levels tested. Observed
clinical remissions will also be presented. Abstract details
include:
As of July 5, 2023, 43 patients (42 R/R AML and 1 HR-MDS) across
8 Dose Levels (DLs) at 10 – 6000 μg/kg/dose were included. Patients
had received a median of 2.0 (1.0 – 10.0) prior lines of treatment
with 13 patients (30.2%) reporting prior hematopoiectic stell cell
transplantation and 36 patients (83.7%) with prior exposure to
venetoclax. In DLs with a highest dose of 1000 μg/kg QW, 5/15
(33.3%) patients achieved a CR (4 CR / 1 CRi) as of the cut-off
date. Data from PK/PD and in vitro mechanistic analyses studying
dose-response relations will also be presented. SAR443579 was well
tolerated up to doses of 6000 μg/kg QW with observed clinical
benefit in patients with R/R AML. The results are consistent with
the predicted favorable safety profile.
ASH abstract details:
Lacutamab
- Oral Presentation Publication Number: 185
Title: Lacutamab in Patients with Relapsed and Refractory
Sézary Syndrome: Results from the Tellomak Phase 2 Trial Session
Name: 624. Hodgkin Lymphomas and T/NK Cell Lymphomas: Clinical
and Epidemiological: Topics in T Cell, Sezary and Hodgkin Lymphomas
Session Date and Time: Saturday, December 9, 2023 3:00 PM
Presenter: Prof Porcu Room: Manchester Grand Hyatt
San Diego, Grand Hall B
- Poster session Publication Number: 3072
Title: Strategies to Develop Anti-KIR Mab Lacutamab in
Patients with Peripheral T-Cell Lymphoma: Preliminary Monotherapy
Clinical Data and Pre-Clinical Combinability Data Session
Name: 624. Hodgkin Lymphomas and T/NK cell Lymphomas: Clinical
and Epidemiological: Poster II Session Date: Sunday,
December 10, 2023 Presentation Time: 6:00 PM - 8:00 PM
Location: San Diego Convention Center, Halls G-H
SAR443579 / IPH6101 (Sanofi
collaboration)
Publication Number: 3474 Title:
First-in-Human Study of the CD123 NK Cell Engager SAR443579 in
Relapsed or Refractory Acute Myeloid Leukemia, B-Cell Acute
Lymphoblastic Leukemia or High Risk-Myelodysplasia: Updated Safety,
Efficacy, Pharmacokinetics and Pharmacodynamics Session
Name: 704. Cellular Immunotherapies: Early Phase and
Investigational Therapies: Poster II Session Date: Sunday,
December 10, 2023 Presentation Time: 6:00 PM-8:00 PM
Location: San Diego Convention Center, Halls G-H
About Innate Pharma
Innate Pharma S.A. is a global, clinical-stage biotechnology
company developing immunotherapies for cancer patients. Its
innovative approach aims to harness the innate immune system
through therapeutic antibodies and its ANKET®
(Antibody-based NK cell Engager
Therapeutics) proprietary platform.
Innate’s portfolio includes lead proprietary program lacutamab,
developed in advanced form of cutaneous T cell lymphomas and
peripheral T cell lymphomas, monalizumab developed with AstraZeneca
in non-small cell lung cancer, as well as ANKET® multi-specific NK
cell engagers to address multiple tumor types.
Innate Pharma is a trusted partner to biopharmaceutical
companies such as Sanofi and AstraZeneca, as well as leading
research institutions, to accelerate innovation, research and
development for the benefit of patients.
Headquartered in Marseille, France with a US office in
Rockville, MD, Innate Pharma is listed on Euronext Paris and Nasdaq
in the US.
Learn more about Innate Pharma at www.innate-pharma.com and
follow us on Twitter and LinkedIn.
Information about Innate Pharma shares
ISIN code Ticker
code LEI
FR0010331421
Euronext: IPH Nasdaq: IPHA
9695002Y8420ZB8HJE29
Disclaimer on forward-looking information and risk
factors
This press release contains certain forward-looking statements,
including those within the meaning of the Private Securities
Litigation Reform Act of 1995. The use of certain words, including
“believe,” “potential,” “expect” and “will” and similar
expressions, is intended to identify forward-looking statements.
Although the company believes its expectations are based on
reasonable assumptions, these forward-looking statements are
subject to numerous risks and uncertainties, which could cause
actual results to differ materially from those anticipated. These
risks and uncertainties include, among other things, the
uncertainties inherent in research and development, including
related to safety, progression of and results from its ongoing and
planned clinical trials and preclinical studies, review and
approvals by regulatory authorities of its product candidates, the
Company’s commercialization efforts and the Company’s continued
ability to raise capital to fund its development. For an additional
discussion of risks and uncertainties which could cause the
company's actual results, financial condition, performance or
achievements to differ from those contained in the forward-looking
statements, please refer to the Risk Factors (“Facteurs de Risque")
section of the Universal Registration Document filed with the
French Financial Markets Authority (“AMF”), which is available on
the AMF website http://www.amf-france.org or on Innate Pharma’s
website, and public filings and reports filed with the U.S.
Securities and Exchange Commission (“SEC”), including the Company’s
Annual Report on Form 20-F for the year ended December 31, 2022,
and subsequent filings and reports filed with the AMF or SEC, or
otherwise made public, by the Company.
This press release and the information contained herein do not
constitute an offer to sell or a solicitation of an offer to buy or
subscribe to shares in Innate Pharma in any country.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20231102430085/en/
Investors Innate
Pharma Henry Wheeler Tel.: +33 (0)4 84 90 32 88
Henry.wheeler@innate-pharma.fr
Media Relations
NewCap Arthur Rouillé Tel.: +33 (0)1 44 71 00 15
innate@newcap.eu
Innate Pharma (EU:IPH)
Graphique Historique de l'Action
De Avr 2024 à Mai 2024
Innate Pharma (EU:IPH)
Graphique Historique de l'Action
De Mai 2023 à Mai 2024